• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

GM-CSF 靶向治疗 COVID-19：基于脆弱基础的方法。

GM-CSF targeting in COVID-19: an approach based on fragile foundations.

机构信息

Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK.

Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, UK.

出版信息

Eur Respir J. 2023 Feb 2;61(2). doi: 10.1183/13993003.02091-2022. Print 2023 Feb.

DOI:10.1183/13993003.02091-2022
PMID:36396141
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9686318/
Abstract

http://bit.ly/3O1AuIo

摘要

http://bit.ly/3O1AuIo

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3e6/9686318/7d20f284dba4/ERJ-02091-2022.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3e6/9686318/7d20f284dba4/ERJ-02091-2022.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3e6/9686318/7d20f284dba4/ERJ-02091-2022.01.jpg

相似文献

1
GM-CSF targeting in COVID-19: an approach based on fragile foundations.GM-CSF 靶向治疗 COVID-19：基于脆弱基础的方法。
Eur Respir J. 2023 Feb 2;61(2). doi: 10.1183/13993003.02091-2022. Print 2023 Feb.
2
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies.针对 COVID-19 肺炎的 GM-CSF：原理与策略。
Front Immunol. 2020 Jul 3;11:1625. doi: 10.3389/fimmu.2020.01625. eCollection 2020.
3
Chronic pharmacological antagonism of the GM-CSF receptor in mice does not replicate the pulmonary alveolar proteinosis phenotype but does alter lung surfactant turnover.在小鼠中慢性药理学拮抗 GM-CSF 受体不会复制肺表面活性物质蛋白沉积症表型，但会改变肺表面活性剂的转化。
Clin Sci (Lond). 2021 Nov 26;135(22):2559-2573. doi: 10.1042/CS20210713.
4
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).一项抗 GM-CSF 单克隆抗体奥替利珠单抗治疗重症 COVID-19 肺炎的随机临床试验（OSCAR）。
Eur Respir J. 2023 Feb 2;61(2). doi: 10.1183/13993003.01870-2021. Print 2023 Feb.
5
Efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in COVID-19 patients: a meta-analysis.GM-CSF 抗体在 COVID-19 患者中的疗效和安全性：一项荟萃分析。
Inflammopharmacology. 2023 Feb;31(1):275-285. doi: 10.1007/s10787-022-01105-9. Epub 2022 Nov 29.
6
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.粒细胞-巨噬细胞集落刺激因子（GM-CSF）作为银屑病的治疗靶点：使用 namilumab（一种特异性人抗 GM-CSF 单克隆抗体）进行的随机对照研究。
Br J Dermatol. 2019 Jun;180(6):1352-1360. doi: 10.1111/bjd.17195. Epub 2018 Nov 2.
7
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.C 反应蛋白的应用，一种 COVID-19 早期治疗的生物标志物，提高了 lenzilumab 的疗效：来自随机 3 期 'LIVE-AIR' 试验的结果。
Thorax. 2023 Jun;78(6):606-616. doi: 10.1136/thoraxjnl-2022-218744. Epub 2022 Jul 6.
8
Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.抗粒细胞-巨噬细胞集落刺激因子单克隆抗体吉西单抗治疗 COVID-19 肺炎：一项随机、双盲、安慰剂对照试验。
Am J Respir Crit Care Med. 2022 Jun 1;205(11):1290-1299. doi: 10.1164/rccm.202108-1859OC.
9
Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment.新冠病毒（COVID-19）导致肺泡巨噬细胞中 GM-CSF 依赖性指令缺失，为吸入 GM-CSF 治疗提供了理论依据。
Cell Rep Med. 2022 Dec 20;3(12):100833. doi: 10.1016/j.xcrm.2022.100833. Epub 2022 Nov 15.
10
EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo.表皮生长因子受体在体外和体内调节角质细胞衍生的粒细胞/巨噬细胞集落刺激因子的表达。
J Invest Dermatol. 2010 Mar;130(3):682-93. doi: 10.1038/jid.2009.336. Epub 2009 Nov 5.

引用本文的文献

1
Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2.深入了解针对 SARS-CoV-2 的保护性和致病性免疫反应的机制。
Mol Immunol. 2023 Apr;156:111-126. doi: 10.1016/j.molimm.2023.03.009. Epub 2023 Mar 10.

本文引用的文献

1
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).一项抗 GM-CSF 单克隆抗体奥替利珠单抗治疗重症 COVID-19 肺炎的随机临床试验（OSCAR）。
Eur Respir J. 2023 Feb 2;61(2). doi: 10.1183/13993003.01870-2021. Print 2023 Feb.
2
Obesity Is Associated with Attenuated Tissue Immunity in COVID-19.肥胖与 COVID-19 中的组织免疫减弱有关。
Am J Respir Crit Care Med. 2023 Mar 1;207(5):566-576. doi: 10.1164/rccm.202204-0751OC.
3
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.
C 反应蛋白的应用，一种 COVID-19 早期治疗的生物标志物，提高了 lenzilumab 的疗效：来自随机 3 期 'LIVE-AIR' 试验的结果。
Thorax. 2023 Jun;78(6):606-616. doi: 10.1136/thoraxjnl-2022-218744. Epub 2022 Jul 6.
4
The Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19.COVID-19 随机临床试验中统计学显著结果的脆弱性。
JAMA Netw Open. 2022 Mar 1;5(3):e222973. doi: 10.1001/jamanetworkopen.2022.2973.
5
Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.抗粒细胞-巨噬细胞集落刺激因子单克隆抗体吉西单抗治疗 COVID-19 肺炎：一项随机、双盲、安慰剂对照试验。
Am J Respir Crit Care Med. 2022 Jun 1;205(11):1290-1299. doi: 10.1164/rccm.202108-1859OC.
6
Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19.分析预测重症 COVID-19 患者对托珠单抗治疗临床应答的因素。
Int J Infect Dis. 2022 Apr;117:56-64. doi: 10.1016/j.ijid.2022.01.040. Epub 2022 Jan 23.
7
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.那昔单抗或英夫利昔单抗对比 COVID-19 住院患者标准治疗（CATALYST）：一项随机、多中心、多臂、多阶段、开放标签、适应性、2 期、概念验证试验。
Lancet Respir Med. 2022 Mar;10(3):255-266. doi: 10.1016/S2213-2600(21)00460-4. Epub 2021 Dec 16.
8
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.伦齐单抗治疗 COVID-19 肺炎住院患者（LIVE-AIR）：一项 3 期、随机、安慰剂对照试验。
Lancet Respir Med. 2022 Mar;10(3):237-246. doi: 10.1016/S2213-2600(21)00494-X. Epub 2021 Dec 1.
9
SARS-CoV-2, COVID-19 and the Ageing Immune System.SARS-CoV-2、COVID-19 和衰老的免疫系统。
Nat Aging. 2021 Sep;1(9):769-782. doi: 10.1038/s43587-021-00114-7. Epub 2021 Sep 14.
10
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients.致病性T细胞和炎性单核细胞在重症COVID-19患者中引发炎症风暴。
Natl Sci Rev. 2020 Jun;7(6):998-1002. doi: 10.1093/nsr/nwaa041. Epub 2020 Mar 13.